Biomarkers in medicine最新文献_第10页

Prognostic value of the CALLY index in predicting mortality in patients with infective endocarditis. CALLY指数预测感染性心内膜炎患者死亡率的预后价值。

IF 2.1 4区医学

Biomarkers in medicine Pub Date : 2026-01-01 Epub Date: 2026-02-12 DOI: 10.1080/17520363.2026.2630028

Huseyin Orta, Cihan Aydin, Aykut Demirkiran, Zarifa Orta

{"title":"Prognostic value of the CALLY index in predicting mortality in patients with infective endocarditis.","authors":"Huseyin Orta, Cihan Aydin, Aykut Demirkiran, Zarifa Orta","doi":"10.1080/17520363.2026.2630028","DOIUrl":"10.1080/17520363.2026.2630028","url":null,"abstract":"Objectives: This study aimed to investigate the predictive value of the C-reactive protein-albumin-lymphocyte (CALLY) index for mortality in patients diagnosed with Infective Endocarditis (IE).Methods: We retrospectively analyzed 100 patients diagnosed with IE based on Duke criteria between 2016 and 2024. The CALLY index was calculated at admission using the formula: [(albumin × lymphocyte count)/CRP]. Demographic, clinical, laboratory, and echocardiographic data were collected.Results: Mortality occurred in 55% of patients. The deceased group had significantly lower CALLY index values compared to survivors (median: 1.7 vs. 6.9, p < 0.001). Multivariate analysis identified male sex (OR 3.791, p = 0.043), diabetes mellitus (OR 4.126, p = 0.022), and a lower CALLY index (OR 0.824, p = 0.005) as independent predictors of mortality, with lower CALLY values being associated with a higher risk of death. The CALLY index demonstrated moderate discriminative power (AUC = 0.792) with a cutoff value of 3.3, which yielded 68.9% sensitivity and 69.1% specificity.Conclusions: The CALLY index, an accessible and cost-effective biomarker, is independently associated with mortality and may serve as a hypothesis-generating tool for risk stratification in IE patients. Its incorporation into routine clinical assessment may enhance early risk stratification and guide management strategies.","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":" ","pages":"87-94"},"PeriodicalIF":2.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12947561/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146177924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of PRKAA2 and LKB1 genetic variants on metabolic alterations in response to metformin-sulfonylurea therapy. PRKAA2和LKB1基因变异对二甲双胍-磺酰脲治疗后代谢改变的影响

IF 2.1 4区医学

Biomarkers in medicine Pub Date : 2026-01-01 Epub Date: 2025-12-30 DOI: 10.1080/17520363.2025.2608954

Aliya Abbas Rizvi, Mohammad Abbas, Asma Imran Ansari, Sushma Verma, Zeba Siddiqi, Farzana Mahdi

{"title":"Impact of PRKAA2 and LKB1 genetic variants on metabolic alterations in response to metformin-sulfonylurea therapy.","authors":"Aliya Abbas Rizvi, Mohammad Abbas, Asma Imran Ansari, Sushma Verma, Zeba Siddiqi, Farzana Mahdi","doi":"10.1080/17520363.2025.2608954","DOIUrl":"10.1080/17520363.2025.2608954","url":null,"abstract":"Background: Metformin-sulfonylurea combination is a widely prescribed as second-line therapy for type 2 diabetes mellitus (T2DM), yet patient responses vary due to individual genetic variation. These variations, particularly in AMP-activated protein kinase (AMPK) and its upstream regulator liver kinase B1 (LKB1), may contribute to differences in treatment response. This study investigated the association of PRKAA2(rs2746338) and LKB1(rs741765) polymorphisms with metformin-sulfonylurea response in T2DM patients.Methods: We enrolled 193 T2DM patients on metformin-sulfonylurea therapy after obtaining written consent. Glycemic and lipid parameters were assessed at baseline and after 3 months. Genotyping was performed by PCR-RFLP and ARMS-PCR for PRKAA2(rs2746338) and LKB1(rs741765), respectively. Statistical analysis was conducted using SPSS v27.Results: Genotype and allele distributions were not significantly different between responders and non-responders. Carriers of PRKAA2(rs2746338) AA and AG and LKB1(rs741765) CT genotypes showed greater FBG reduction (p = 0.028, p < 0.001, and p < 0.001 respectively). Additionally, PRKAA2(rs2746338) AG and LKB1(rs741765) CT genotypes showed significant improvements in PPG, HbA1c, triglycerides, and LDL (all p < 0.05).Conclusion: We conclude that PRKAA2(rs2746338) and LKB1(rs741765) variants were linked to favorable glycemic and lipid changes, suggesting reduced cardiovascular risk in T2DM. These variants may serve as pharmacogenetic markers for personalized therapy, warranting validation in larger studies.","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":" ","pages":"27-35"},"PeriodicalIF":2.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12947565/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145854399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Contemporary perspective and practical application of glutamate dehydrogenase in nonclinical studies. 谷氨酸脱氢酶在非临床研究中的当代观点和实际应用。

IF 2.1 4区医学

Biomarkers in medicine Pub Date : 2025-12-01 DOI: 10.1080/17520363.2025.2595911

Ravindra C Kodihalli, Mehrdad Ameri, Kevin S Baker, Samantha C Faber, Armando R Irizarry Rovira, Jonathan P Jackson, Leah M Norona, William R Proctor, Jessica M Caverly Rae, Arie Regev, Melanie Z Sakatis, Dominic P Williams, Doris Zane, Payal Rana

{"title":"Contemporary perspective and practical application of glutamate dehydrogenase in nonclinical studies.","authors":"Ravindra C Kodihalli, Mehrdad Ameri, Kevin S Baker, Samantha C Faber, Armando R Irizarry Rovira, Jonathan P Jackson, Leah M Norona, William R Proctor, Jessica M Caverly Rae, Arie Regev, Melanie Z Sakatis, Dominic P Williams, Doris Zane, Payal Rana","doi":"10.1080/17520363.2025.2595911","DOIUrl":"10.1080/17520363.2025.2595911","url":null,"abstract":"The use of biomarkers in nonclinical species has gained significant attention for improving predictive accuracy in toxicological studies and early disease detection. This article focuses on glutamate dehydrogenase (GLDH), a mitochondrial enzyme currently under regulatory review for qualification as a clinical biomarker to detect hepatocellular injury in patients with elevated serum transaminases due to muscle injury. GLDH has shown effectiveness in evaluating liver injury, particularly in rodents and non-human primates. This opinion paper outlines the potential of GLDH as a biomarker for monitoring drug-induced liver injury (DILI), drawing on the expertise of authors from the IQ DILI Initiative. It highlights industry consensus on GLDH use in nonclinical studies and its relevance in toxicology and drug development. The advantages and challenges of GLDH are discussed, including its interpretation as a mechanistic biomarker with translational relevance. Recent advancements in GLDH research in nonclinical species with different disease backgrounds and therapeutic modalities are explored. The integration of GLDH with other biomarkers to enhance the overall assessment of nonclinical species is reviewed. Our collective consensus opinion on GLDH is that it may offer an additional benefit over traditional biomarkers for hepatotoxicity, particularly when test articles cause increased serum transaminases due to concurrent muscle injury.","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":" ","pages":"1181-1187"},"PeriodicalIF":2.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12758256/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145653286","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Development of a novel diagnostic model integrating microRNAs and GALAD for HBV-related hepatocellular carcinoma. 整合microrna和GALAD的新型hbv相关肝细胞癌诊断模型的建立

IF 2.1 4区医学

Biomarkers in medicine Pub Date : 2025-12-01 Epub Date: 2025-12-11 DOI: 10.1080/17520363.2025.2600248

Yihui Yang, Anli Jin, Yan Zhou, Wenhao Wu, Chunyan Zhang, Baishen Pan, Beili Wang, Yunfan Sun, Wei Guo

{"title":"Development of a novel diagnostic model integrating microRNAs and GALAD for HBV-related hepatocellular carcinoma.","authors":"Yihui Yang, Anli Jin, Yan Zhou, Wenhao Wu, Chunyan Zhang, Baishen Pan, Beili Wang, Yunfan Sun, Wei Guo","doi":"10.1080/17520363.2025.2600248","DOIUrl":"10.1080/17520363.2025.2600248","url":null,"abstract":"Aims: As primary hepatocellular carcinoma (HCC) is a prevalent digestive tract malignancy, identifying novel biomarkers for early diagnosis and prognosis is crucial. This study combined specific miRNAs with the GALAD model to create a new diagnostic model for hepatitis B virus (HBV)-related HCC.Patients & methods: From 2020 to 2022, 884 patients from Zhongshan Hospital were enrolled, including 430 HBV-related HCC, 275 HBV-related chronic liver disease (CLD), and 179 healthy donors (HD). Stepwise regression selected features, and multivariable logistic regression built the GALADM model. A nomogram integrating age, gender, serum markers, and a score derived from seven plasma cell-free microRNAs (miRNA7) was developed.Results: MiRNA7 value was higher in HCC patients and rose with disease progression. The GALADM model showed superior diagnostic performance, with AUCs of 0.87, 0.96, and 0.90 when distinguishing HCC from CLD, HD, and CLD+HD, outperforming the GALAD model and single markers. It also excelled in diagnosing early-stage and Alpha-fetoprotein (AFP)-negative HCC. The nomogram had an AUC of 0.977 and proved clinically useful.Conclusion: The GALADM model, combining miRNA7 with the GALAD model, surpasses the original GALAD model, enabling early-stage and AFP-negative HCC diagnosis.","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":" ","pages":"1255-1265"},"PeriodicalIF":2.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12758346/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145721074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hepatic steatosis/fibrosis related biomarkers in patients with metabolic dysfunction-associated steatotic liver disease. 代谢功能障碍相关脂肪性肝病患者的肝脂肪变性/纤维化相关生物标志物

IF 2.1 4区医学

Biomarkers in medicine Pub Date : 2025-12-01 Epub Date: 2025-11-27 DOI: 10.1080/17520363.2025.2595909

Zhi Peng, Zijin Wang, Juan Wang, Xuefeng Li

{"title":"Hepatic steatosis/fibrosis related biomarkers in patients with metabolic dysfunction-associated steatotic liver disease.","authors":"Zhi Peng, Zijin Wang, Juan Wang, Xuefeng Li","doi":"10.1080/17520363.2025.2595909","DOIUrl":"10.1080/17520363.2025.2595909","url":null,"abstract":"Aims: To explore hepatic steatosis and fibrosis related biomarkers in patients with metabolic dysfunction-associated steatotic liver disease (MASLD).Patients and methods: Total 158 patients with MASLD were tested with Fibroscan to measure hepatic steatosis value (CAP value) and liver fibrosis value (E value), and divided into mild group (31 cases), moderate (49 cases), and severe fatty liver group (78 cases) according to CAP value; no fibrosis group (106 cases), early fibrosis group (38 cases), and advanced fibrosis and cirrhosis group (14 cases) according to E value.Results: E value was negatively correlated with CHOL and LDL, and CAP value was positively correlated with LDL. TG, CHOL and LDL levels in severe fatty liver group were significantly higher than those in mild fatty liver group; TG and LDL levels in moderate fatty liver group were higher than those in mild fatty liver group. TG level in early fibrosis group was significantly higher than that in advanced fibrosis and cirrhosis group.Conclusion: With the aggravation of hyperlipidemia, hepatic steatosis increases; with the aggravation of liver fibrosis, TG level decreases. Lipid metabolism worsens with the degree of steatosis. LDL is related to the severity of hepatic steatosis and fibrosis.","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":" ","pages":"1239-1243"},"PeriodicalIF":2.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12758338/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145630048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Combined predictive value of serum endothelin-1 and fibroblast growth factor-23 for in-stent restenosis following vertebral artery stenting: a novel biomarker strategy. 血清内皮素-1和成纤维细胞生长因子-23对椎动脉支架内再狭窄的联合预测价值：一种新的生物标志物策略。

IF 2.1 4区医学

Biomarkers in medicine Pub Date : 2025-12-01 Epub Date: 2025-12-10 DOI: 10.1080/17520363.2025.2600707

Yanxuan Hu, Cong Wu, Chunli Wu, Yuan Liu, Changyang Zhong

{"title":"Combined predictive value of serum endothelin-1 and fibroblast growth factor-23 for in-stent restenosis following vertebral artery stenting: a novel biomarker strategy.","authors":"Yanxuan Hu, Cong Wu, Chunli Wu, Yuan Liu, Changyang Zhong","doi":"10.1080/17520363.2025.2600707","DOIUrl":"10.1080/17520363.2025.2600707","url":null,"abstract":"Purpose: In-stent restenosis (ISR) after vertebral artery stenting (VAS) affects 20-35% of patients, yet current risk stratification lacks sensitivity for early intervention. We propose the first combined biomarker model integrating endothelin-1 (ET-1) and fibroblast growth factor 23 (FGF23) to address this gap.Methods: A prospective cohort study was conducted involving 148 patients who underwent VAS between 2020 and 2024. Blood samples were collected preoperatively to measure ET-1 and FGF23 levels. ISR was defined as a stenosis of at least 50% on follow-up imaging. Statistical analyses included multivariable logistic regression and receiver operating characteristic (ROC) curve evaluations to assess the biomarkers' performance.Results: ISR occurred in 34 patients (23%). Both ET-1 and FGF23 levels were significantly higher in the ISR group. Multivariate analysis identified ET-1, FGF23, stent length, and LDL-C levels as independent predictors of ISR. The combined model using both biomarkers demonstrated superior discriminative performance (AUC = 0.96) compared to individual markers (AUC = 0.73 for ET-1 and AUC = 0.77 for FGF23). The model achieved sensitivity and specificity of 92.3% and 89.7%, respectively.Conclusion: The combined assessment of serum ET-1 and FGF23 exhibits a synergistic predictive role for ISR after VAS. The ET-1/FGF23 model enables personalized risk stratification, guiding targeted therapies to reduce recurrent ischemic events and healthcare costs.","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":" ","pages":"1247-1253"},"PeriodicalIF":2.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12758235/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145713322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Meta-analysis of preoperative CALLY index for predicting the prognosis of cancer. 术前CALLY指数预测肿瘤预后的meta分析。

IF 2.1 4区医学

Biomarkers in medicine Pub Date : 2025-12-01 Epub Date: 2025-12-06 DOI: 10.1080/17520363.2025.2600696

Congying Li, Wenlong Zhou, Xin Zhao, Yanli Sun, Jianfeng Zang, Shujing Wang

{"title":"Meta-analysis of preoperative CALLY index for predicting the prognosis of cancer.","authors":"Congying Li, Wenlong Zhou, Xin Zhao, Yanli Sun, Jianfeng Zang, Shujing Wang","doi":"10.1080/17520363.2025.2600696","DOIUrl":"10.1080/17520363.2025.2600696","url":null,"abstract":"Objective: This study aims to evaluate the predictive value of the CALLY index in cancer prognosis via systematic review and meta-analysis.Methods: PubMed, Web of Science, Embase, and Cochrane were searched up to November 2024. Study quality was evaluated using the Newcastle-Ottawa Scale (NOS), and meta-analysis was performed with STATA 17.0.Results: Among 21 cohort studies,the findings indicated that, regarding overall survival (OS), a low CALLY index was correlated with a 113% elevated likelihood of all-cause mortality compared to those with a higher CALLY index (risk ratio [RR] = 0.47, 95% confidence intervals [95%CI]: 0.42-0.53). An 85% elevated risk of disease-free survival (DFS) and relapse-free survival (RFS) was observed in individuals with a low CALLY index (pooled RR = 0.54, 95%CI: 0.46-0.63). Moreover, a lower CALLY index was correlated with a significantly greater tumor burden (standardized mean difference (SMD) = -0.64, 95%CI: -0.76-0.52). The stage-specific analysis demonstrated that a low CALLY index significantly increased the risk of cancer progression by 54% in individuals at stage II (RR = 0.65, 95%CI: 0.43-0.98) and by 67% in individuals at stage III (RR = 0.60, 95%CI: 0.43-0.86).Conclusion: The CALLY index independently predicts adverse cancer outcomes.","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":" ","pages":"1293-1304"},"PeriodicalIF":2.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12758343/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145687055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Serum periostin: a sentinel for malignancy risk in kidney transplant recipients. 血清骨膜素：肾移植受者恶性肿瘤风险的哨兵。

IF 2.1 4区医学

Biomarkers in medicine Pub Date : 2025-12-01 Epub Date: 2025-12-19 DOI: 10.1080/17520363.2025.2595907

Anna Sączek, Krzysztof Batko, Małgorzata Banaszkiewicz, Jolanta Małyszko, Ewa Koc-Żórawska, Marcin Żórawski, Karolina Niezabitowska, Katarzyna Siek, Andrzej Kraśniak, Alina Bętkowska-Prokop, Katarzyna Krzanowska, Marcin Krzanowski

{"title":"Serum periostin: a sentinel for malignancy risk in kidney transplant recipients.","authors":"Anna Sączek, Krzysztof Batko, Małgorzata Banaszkiewicz, Jolanta Małyszko, Ewa Koc-Żórawska, Marcin Żórawski, Karolina Niezabitowska, Katarzyna Siek, Andrzej Kraśniak, Alina Bętkowska-Prokop, Katarzyna Krzanowska, Marcin Krzanowski","doi":"10.1080/17520363.2025.2595907","DOIUrl":"10.1080/17520363.2025.2595907","url":null,"abstract":"Background: Periostin (POSTN) is a matricellular protein involved in kidney fibrosis and inflammation but also linked to tumor progression and regulation of the local microenvironment.Aims: This study aimed to evaluate the association between serum POSTN, transgelin (TAGLN) and highly sensitive interleukin 6 (hsIL-6) and de novo malignancy occurrence post kidney transplant (KTx).Methods: Serum concentrations of POSTN, TAGLN, and hsIL-6 were measured in 127 KTRs and compared with 32 healthy controls. Patients were followed for a median (IQR) of 29 (25-32) months.Results: Log-transformed serum POSTN concentrations were lower in the KTx group (mean [SD]: 6.80[0.53] vs. 7.06[0.33] pmol/l), whereas transgelin (4.62[0.34] vs. 4.30[0.29] ng/mL) and hsIL-6 (1.51[0.50] vs. 0.99[0.37] pg/mL) were elevated (p < 0.001 for all). Final model showed satisfactory discrimination (AUC 0.83; 95% CI 0.74-0.91). Patients in the moderate POSTN zone were characterized higher odds of malignancy (OR 4.40; 95% CI 1.21-16.91, p = 0.011). Higher POSTN levels were independently associated with time post-KTx (β = 0.20; p < 0.001). Lower TAGLN levels were observed in older patients (β = -0.005; p = 0.011), those with CV disease (β = -0.200; p = 0.008) and among smokers (β = -0.19; p = 0.026).Conclusions: In patients post-KTx, elevated serum POSTN is an independent predictor of new-onset malignancy. Further prospective evaluation is warranted.","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":" ","pages":"1199-1209"},"PeriodicalIF":2.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12758172/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145793370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Predictive value of miR-21 and miR-486 in clock-guided minimally invasive surgery for pulmonary nodules. miR-21和miR-486在时钟引导下肺结节微创手术中的预测价值。

IF 2.1 4区医学

Biomarkers in medicine Pub Date : 2025-12-01 Epub Date: 2025-12-09 DOI: 10.1080/17520363.2025.2595913

Zheng Wang, Wei Yan, Qiang Wang, Huining Liu, Qiang Liu, Qing Tian, Zhijie Li, Jinfeng Liu, Yingchun Ren

{"title":"Predictive value of miR-21 and miR-486 in clock-guided minimally invasive surgery for pulmonary nodules.","authors":"Zheng Wang, Wei Yan, Qiang Wang, Huining Liu, Qiang Liu, Qing Tian, Zhijie Li, Jinfeng Liu, Yingchun Ren","doi":"10.1080/17520363.2025.2595913","DOIUrl":"10.1080/17520363.2025.2595913","url":null,"abstract":"Objective: This study evaluated the prognostic significance of miR-21 and miR-486 expression in patients undergoing clock-guided minimally invasive surgery for pulmonary nodules.Methods: In this prospective cohort study, intraoperative tissues from 138 lung cancer patients were analyzed. MiRNA expression was quantified via RT-qPCR, and patients were stratified into high- and low-expression groups using ROC-determined cutoffs. Postoperative outcomes, including residual nodule characteristics and survival, were monitored.Results: At 6 months postoperatively, the high-expression group demonstrated significantly larger residual nodules (1.06 vs. 0.73 cm, p < 0.001), higher density (p = 0.003), and elevated metabolic activity (p = 0.014). This group also experienced shorter median overall survival (OS) (17.4 vs. 21.6 months, p = 0.003) and progression-free survival (PFS) (11.5 vs. 16.6 months, p = 0.012). In multivariable analysis, both miR-21 (HR = 1.75, p = 0.023) and miR-486 (HR = 1.68, p = 0.031) remained independent predictors of poor OS after adjusting for clinical covariates.Conclusion: Elevated miR-21 and miR-486 expression predicts aggressive tumor behavior and poor survival after precise nodule resection, highlighting their potential as biomarkers for postoperative risk stratification.","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":" ","pages":"1221-1225"},"PeriodicalIF":2.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12758226/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145707361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Reply to comment on "Plasma-derived circALG8 and circCAMTA1 as a panel for early diagnosis of non-small cell lung cancer". 回复关于“血浆源性circALG8和circCAMTA1作为非小细胞肺癌早期诊断指标”的评论。

IF 2.1 4区医学

Biomarkers in medicine Pub Date : 2025-12-01 Epub Date: 2025-12-15 DOI: 10.1080/17520363.2025.2600708

Yufei Sheng, Lulu Yang, Boyang Wang, Zhiqi Hong, Jin Guo, Chengwei Zhou, Tao Li, Wentao Hu, Zhaohui Gong

引用次数: 0